Literature DB >> 17931845

Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer.

P Jain1, R D Hunter, J E Livsey, C Coyle, R Swindell, S E Davidson.   

Abstract

AIMS: To determine the outcome and morbidity after radiotherapy for locally recurrent cervical cancer.
MATERIALS AND METHODS: Women who presented with locally recurrent cervical cancer after surgery alone during 1985 and 1997 were identified from the hospital database. Data were collected and analysed to include the stage at first diagnosis, staging investigations before surgery, the surgical procedure, the indication for radiotherapy, the type of radiotherapy, morbidity and survival.
RESULTS: In total, 130 women had radical external beam radiotherapy and/or intracavitary brachytherapy for locoregional recurrence during the defined study period. The 5-year disease-specific survival for the study population was 40.2%. Women who were treated for vault recurrence had a significantly better 5-year disease-free survival compared with women who developed nodal recurrence alone (55.4% vs 12.5%). This group of women also had a significantly slower rate of disease progression after radiotherapy than women with nodal recurrence (48.7% vs 87.5%, P=0.0001).
CONCLUSION: Radical radiotherapy alone is able to salvage 55% of vaginal vault recurrences after surgery for cervical cancer with minimal late toxicity. Salvage rates in women with pelvic nodal recurrences are considerably lower. Chemoradiotherapy using intensity-modulated radiotherapy to deliver an escalated radiotherapy dose needs to be pursued to improve locoregional control.

Entities:  

Mesh:

Year:  2007        PMID: 17931845     DOI: 10.1016/j.clon.2007.08.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  8 in total

1.  Salvage radiotherapy with or without concurrent chemotherapy for pelvic recurrence after hysterectomy alone for early-stage uterine cervical cancer.

Authors:  Sang-Won Kim; Mison Chun; Hee-Sug Ryu; Suk-Joon Chang; Tae Wook Kong; Eun Ju Lee; Yong Hee Lee; Young-Taek Oh
Journal:  Strahlenther Onkol       Date:  2017-03-29       Impact factor: 3.621

2.  Treatment options in recurrent cervical cancer (Review).

Authors:  Angiolo Gadducci; Roberta Tana; Stefania Cosio; Luca Cionini
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 3.  Use of stereotactic radiosurgery in the treatment of gynecologic malignancies: A review.

Authors:  Beverly Long; Ramez N Eskander; Krishnansu S Tewari
Journal:  World J Radiol       Date:  2014-06-28

4.  Radiotherapy for Vaginal Recurrences of Cervical Cancer in Patients After Prior Surgery: Analysis of Effect and Prognostic Factors.

Authors:  Junfang Yan; Ziye Zheng; Jiawei Zhu; Ke Hu; Xiaorong Hou; Jie Shen; Xin Lian; Shuai Sun; Zheng Miao; Jing Shen; Hui Guan; Qingyu Meng; Fuquan Zhang
Journal:  Front Oncol       Date:  2021-09-13       Impact factor: 6.244

Review 5.  Defining the role of high-dose radiation in oligometastatic & oligorecurrent cervical cancer.

Authors:  Akshay Mangaj; Supriya Chopra; Remi A Nout
Journal:  Indian J Med Res       Date:  2021-08       Impact factor: 5.274

6.  RapidArc for centrally recurrent cervical cancer in the vaginal cuff following primary surgical therapy: a case report.

Authors:  I Lalya; A Maghous; E Marnouche; N Zaghba; K Andaloussi; M Elmarjany; K Hadadi; H Sifat; H Mansouri
Journal:  World J Surg Oncol       Date:  2016-01-22       Impact factor: 2.754

7.  Chemoradiation and the Role of Adjuvant Chemotherapy in Lymph Nodal-Metastatic Cervical Cancer.

Authors:  Nasir Ali; Azmina Tajdin Valimohammad; Ahmed Nadeem Abbasi; Muhammad Atif Mansha; Asim Hafiz; Bilal Mazhar Qureshi
Journal:  J Glob Oncol       Date:  2017-06-12

8.  Surgery followed by concurrent radiochemotherapy as treatment for patients with locally recurrent cervical cancer.

Authors:  Xiang Zhang; Zhongbo Chen; Jianhong Chen; Junjian Wang; Yingchang Wang; Jianqing Zhu
Journal:  Transl Cancer Res       Date:  2021-10       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.